Corvia Medical, Inc.
Privately held medical device company headquartered in Tewksbury, MA focused on development, clinical evaluation, regulatory approval, and commercialization of a transcatheter interatrial shunt implant intended to reduce left atrial pressure and treat heart failure with preserved or mildly reduced ejection fraction. The company has led multi-center randomized, sham-controlled clinical programs, published long-term outcome and imaging data, and pursued regulatory clearances including CE certification in the EU and FDA Breakthrough Device designation.
Industries
N/A
Nr. of Employees
small (1-50)
Corvia Medical, Inc.
Patents
Apparatus and methods to create and maintain an intra-atrial pressure relief opening
US-12303119-B2
View DetailsApparatus and methods to create and maintain an intra-atrial pressure relief opening
US-11589854-B2
View Details
Apparatus and methods to create and maintain an intra-atrial pressure relief opening
US-12303119-B2
View DetailsApparatus and methods to create and maintain an intra-atrial pressure relief opening
US-11589854-B2
View DetailsProducts
Interatrial shunt implant (transcatheter)
A catheter-delivered implant that creates a controlled passage between the left and right atria to reduce elevated left atrial pressure in patients with heart failure with preserved or mildly reduced ejection fraction.
Interatrial shunt implant (transcatheter)
A catheter-delivered implant that creates a controlled passage between the left and right atria to reduce elevated left atrial pressure in patients with heart failure with preserved or mildly reduced ejection fraction.
Expertise Areas
- Transcatheter structural heart device development
- Clinical trial design and execution (randomized, sham-controlled)
- Heart failure therapeutics (HFpEF/HFmrEF)
- Regulatory strategy and submissions (FDA, EU MDR)
Key Technologies
- Transcatheter implantable interatrial shunt
- Catheter-based percutaneous implantation
- Invasive exercise hemodynamic testing
- Echocardiographic serial imaging
News & Updates
Company announced closing of a $55 million funding round to complete an international confirmatory trial and support FDA submission of an atrial shunt implant.
Announcement of CE certification for the atrial shunt system under EU MDR 2017/745 and ongoing confirmatory international trial enrollment.
Publication of three-year REDUCE LAP-HF II results reporting reduced heart failure event rates and improved quality of life in a responder subgroup.
Publication reporting favorable long-term effects of atrial shunting on cardiac structure and function.
Company announced closing of a $55 million funding round to complete an international confirmatory trial and support FDA submission of an atrial shunt implant.
Announcement of CE certification for the atrial shunt system under EU MDR 2017/745 and ongoing confirmatory international trial enrollment.
Publication of three-year REDUCE LAP-HF II results reporting reduced heart failure event rates and improved quality of life in a responder subgroup.
Publication reporting favorable long-term effects of atrial shunting on cardiac structure and function.